ArticleFrontiers in oncology2026
Initial observations on dose optimization in
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of low-dose versus high-dose iodine-125 ( Methods: This study retrospectively analyzed 62 patients with recurrent glioblastoma who underwent magnetic resonance (MR) combined with three-dimensional printed template-guided ¹² Results: The 6-month ORR was 61.9% in the 120-140 Gy group and 73.2% in the 140-160 Gy group, with no statistically significant difference between the two groups (P = 0.362). The 1-year survival rate was 42.9% and 68.3% in the low- and high-dose groups, respectively (P = 0.053). Median OS was statistically longer in the high-dose group (13.7 months vs. 11.2 months, P = 0.001). Symptomatic brain edema occurred in 2 cases (Grade 2) in the low-dose group, and 10 cases in the high-dose group (7 Grade 2, 3 Grade 3). All 12 patients received corticosteroid and mannitol therapy, resulting in significant alleviation of clinical symptoms. Conclusion: ¹²
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.